Atrium Innovations supports Wobenzym(R) brand development in Germany

Atrium Innovations Inc. (TSX: ATB), a leading developer, manufacturer and marketer of science-based and professionally supported products for the Health and Nutrition industry, today announced various initiatives to support the development of its Wobenzym(R) brand in Germany.

Atrium announces that Mucos Pharma, a subsidiary of Atrium, has initiated the phase out of Wobenzym(R) N in Germany earlier than initially anticipated. Concurrently, Mucos Pharma is launching a new marketing campaign for Wobenzym(R) P, a natural enzyme-based product with an active OTC drug registration. Wobenzym(R) P will be commercialized like its predecessor, Wobenzym(R) N, as systemic enzyme therapy. As planned, Mucos Pharma intends to launch a new formulation of Wobenzym(R) to be sold as a food supplement in Germany and other Western European countries in early 2010.